CD3 Binding Molecules Patent for Anticancer Antibodies

The EPO published patent application EP3947456A1 for CD3 binding molecules filed by Merus B.V. The invention relates to anticancer antibodies and falls under IPC classifications C07K 16/28 (immunoglobulins/antibodies) and A61P 35/00 (antineoplastic agents). The designated states include all EPO member states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR).

This is a routine patent publication notice with no compliance obligations. Competitors developing CD3 bispecific antibodies or T-cell engaging therapies should review the patent claims for potential freedom-to-operate concerns. No immediate action is required as this is an informational publication of a pending application.